Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which heart cocktail works best during bypass? small study seeks answers

NCT ID NCT07386990

Knowledge-focused Sponsor: Region Skane Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two different solutions used to protect the heart during coronary artery bypass surgery. Forty adults having non-emergency bypass surgery took part. Researchers measured heart enzyme levels and other recovery signs in the first two days after surgery to see which solution worked better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

40 people

The number who actually took part.

Started

Jun 2021

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients scheduled for non urgent, single procedure coronary artery bypass grafting surgery at Skåne university hospital in Lund Sweden Exclusion Criteria: \*Heart failure (=Left ventricular ejection fraction less than 40 %). * Moderate and severe aortic valve insufficiency. * Type 1 diabetes. * Renal insufficiency (=estimated glomerular filtration rate \<60 mL/min/1,73m2) * Not communicating in Swedish language. * Previous cardiac surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardioplegia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardioplegia Cardiopulmonary bypass Coronary artery bypass graft (CABG) Perioperative myocardial injury

Contacts and locations

Locations

  • Cardiothoracic surgery department, Skåne university hospital, Lund

    Lund, 22242, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.